Chronic Migraine

Cady, Roger; Durham, Paul L.

doi:10.1016/b978-0-12-800901-7.00009-4

Cited by 3 publications

(2 citation statements)

References 99 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Scher et al 39 reported similar peak prevalence of migraine to ours (between the ages of 20-30 years). Cady et al 40 reported earlier peak prevalence (~13 years). However, Stovner et al 36 reported a later peak prevalence (~40 years) which was pronouncedly declined in women compared to men.…”

Section: Discussionmentioning

confidence: 94%

Migraine in Assiut Governorate, Egypt: epidemiology, risk factors, comorbid conditions and predictors of change from episodic to chronic migraine

Kandil

Hamed

Fadel

et al. 2016

Neurological Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Migraine in Assiut Governorate, Egypt: epidemiology, risk factors, comorbid conditions and predictors of change from episodic to chronic migraine

Kandil

Hamed

Fadel

et al. 2016

Neurological Research

View full text Add to dashboard Cite

show abstract

“…Phenotype should not be simply a checklist used to make a diagnosis, but an in-depth patient-focused understanding of how the events and symptoms of migraine unfold over the duration of an attack and integrating this understanding into successful treatment. 10 For example, a migraine with an abrupt onset associated early nausea is likely to respond better to a parenteral therapy while an attack phenotype associated with recurrence may respond better to an acute intervention with a long half-life.…”

Section: The Five “Ps”mentioning

confidence: 99%

Managing migraine by patient profile: role of frovatriptan

Cady¹,

Farmer²

2016

PPA

View full text Add to dashboard Cite

For the last quarter of a century, triptans have been available for acute treatment of migraine but with little guidance on which of the different triptan products to use for which patient or which attack of migraine. In this article, we propose a structured approach to analysis of individual migraine attacks and patient characteristics as a means of defining and optimizing acute intervention. Assessment of patient and attack profiles includes the “5-Ps”: pattern, phenotype, patient, pharmacology, and precipitants. Attending to these five components of information can assist in developing an individualized behavioral, pharmacological, and nonpharmacological comprehensive treatment plan for most migraine patients. This clinical approach is then focused on frovatriptan because of its unique molecular signature and potential novel clinical applications. Frovatriptan like all triptans is indicated for acute treatment of migraine but its role has been explored in management of several unique migraine phenotypes. Frovatriptan has the longest half-life of any triptan and consequently is often promoted for acute treatment of migraine of longer duration. It has also been studied as a short-term preventive treatment in women with menstrual-related migraine. Given that 60% of female migraineurs suffer from menstrual-related migraine, this population is the obvious group for continued study. Small studies have also explored frovatriptan’s use in treating migraine predicted by premonitory symptoms as a preventive for the headache phase of migraine. By identifying patient and attack profiles, clinicians may effectively determine the viability of frovatriptan as an effective pharmacological intervention for migraine.

show abstract